Treatment Patterns and Survival Outcomes in Korean Patients With Metastatic Hormone-Sensitive Prostate Cancer in a Real-World Setting
10.22465/juo.255000800040
- Author:
Sung-Hee OH
1
;
Eunjung CHOO
;
Jae Young JOUNG
;
Sung Gu KANG
;
Yoon CHO
;
Chang Wook JEONG
;
Hankil LEE
Author Information
1. BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Korea
- Publication Type:Original Article
- From:
Journal of Urologic Oncology
2025;23(3):236-246
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:With the emergence of next-generation therapies, real-world evaluation of current treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC) is essential. This study aimed to investigate the clinical characteristics, primary treatment patterns, and survival outcomes of Korean patients with mHSPC.
Materials and Methods:A nationwide, population-based retrospective cohort study was conducted using National Health Insurance claims data from 2011 to 2020, encompassing all Korean patients diagnosed with prostate cancer (n=217,895). Patient demographics, initial treatment patterns within 3 months of mHSPC diagnosis, time to initiation of metastatic castration-resistant prostate cancer (mCRPC) therapy, and survival outcomes were analyzed.
Results:Primary treatment patterns for 10,821 newly diagnosed mHSPC patients were generally similar. Approximately half received first-line androgen deprivation therapy (ADT). Most (68.8%–76.3%) were treated with combination therapy consisting of a luteinizing hormone-releasing hormone (LHRH) agonist and a first-generation antiandrogen, while 5.8%–8.0% received ADT alone. Among 1,418 patients diagnosed in 2015, 20.9% initiated mCRPC therapy at a median of 14.6 months. Median times to initial mCRPC drug use were 14.7 months for those on combination therapy and 19.7 months for those on LHRH agonists alone. Median overall survival (OS) was 61.3 months for all patients, 37.0 months for combination therapy, 51.5 months for LHRH agonists, and 25.5 months for patients with visceral metastases.
Conclusion:Most patients with newly diagnosed mHSPC received combination therapy with LHRH agonists and first-generation antiandrogens. In this real-world cohort, patients treated with LHRH agonists demonstrated longer OS and delayed initiation of mCRPC-directed therapy compared with those receiving combination therapy.
